News
TELA
1.110
-2.20%
-0.025
Weekly Report: what happened at TELA last week (1229-0102)?
Weekly Report · 2d ago
Weekly Report: what happened at TELA last week (1222-1226)?
Weekly Report · 12/29/2025 09:19
Small Medtech TELA Bio Takes On Becton Dickinson, Alleges Hernia Mesh Monopoly
Benzinga · 12/23/2025 13:48
Becton, Dickinson accused of hindering competition in hernia mesh market
Seeking Alpha · 12/22/2025 22:54
Weekly Report: what happened at TELA last week (1215-1219)?
Weekly Report · 12/22/2025 09:19
Canaccord Genuity Keeps Their Buy Rating on TELA Bio (TELA)
TipRanks · 12/17/2025 12:09
Weekly Report: what happened at TELA last week (1208-1212)?
Weekly Report · 12/15/2025 09:20
TELA Bio Grants Restricted Stock Units to New Employees
Reuters · 12/12/2025 21:05
TELA BIO ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/12/2025 21:05
Lake Street Keeps Their Buy Rating on TELA Bio (TELA)
TipRanks · 12/12/2025 13:45
Tela Bio files to sell 2M shares of common stock for holders
TipRanks · 12/12/2025 12:15
TELA BIO INC - REGISTERS 2,000,000 SHARES FOR RESALE - SEC FILING
Reuters · 12/12/2025 12:11
Weekly Report: what happened at TELA last week (1201-1205)?
Weekly Report · 12/08/2025 09:20
TELA Bio Is Maintained at Buy by Lake Street
Dow Jones · 12/01/2025 17:13
TELA Bio Price Target Cut to $3.00/Share From $6.00 by Lake Street
Dow Jones · 12/01/2025 17:13
Lake Street Maintains Buy on TELA Bio, Lowers Price Target to $3
Benzinga · 12/01/2025 17:03
Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Centessa Pharmaceuticals (CNTA)
TipRanks · 12/01/2025 14:10
Tela Bio price target lowered to $3 from $6 at Lake Street
TipRanks · 12/01/2025 13:45
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 12/01/2025 12:05
Weekly Report: what happened at TELA last week (1124-1128)?
Weekly Report · 12/01/2025 09:19
More
Webull provides a variety of real-time TELA stock news. You can receive the latest news about Tela Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TELA
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.